AstraZeneca said it will reduce its US sales force by appx. 1,150 leadership positions and sale s representatives, roughly 24% of the Co's sales organisation in the US. The Co added: "This change to the US sales force is incremental to the ongoing second phase of the company's restructuring programme that was announced in January 2010. As a result, a discrete restructuring cost associated with today's announced changes, estimated at between $50 million to $100 million, will be charged in the fourth quarter of 2011."
